Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Sep 5, 2024 · CIK: 882361
Sentiment: neutral
Topics: disclosure, financials, regulation-fd
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Sept 5th, covering Reg FD and financials. Standard update.
AI Summary
Aptose Biosciences Inc. filed an 8-K on September 5, 2024, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is based in Toronto, Canada, and operates in the biological products sector.
Why It Matters
This filing provides updates on Aptose Biosciences' regulatory disclosures and financial reporting, which are important for investors to understand the company's current status and compliance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial statements and regulatory information, not indicating any specific new risks.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- September 5, 2024 (date) — Date of earliest event reported
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- 001-32001 (other) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 5, 2024.
What are some of the former names of Aptose Biosciences Inc.?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which industry sector does Aptose Biosciences Inc. operate?
Aptose Biosciences Inc. operates in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.
What is the SEC file number for Aptose Biosciences Inc.?
The SEC file number for Aptose Biosciences Inc. is 001-32001.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-09-05 16:20:21
Filing Documents
- f8k_090524.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 14KB
- 0001171843-24-005087.txt ( ) — 227KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_090524_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 5, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated September 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: September 5, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer